SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-044938
Filing Date
2024-04-17
Accepted
2024-04-17 09:10:29
Documents
13
Period of Report
2024-04-12
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acor-20240412.htm   iXBRL 8-K 41142
2 EX-99.1 acor-ex99_1.htm EX-99.1 15530
3 GRAPHIC img123754176_0.jpg GRAPHIC 6064
  Complete submission text file 0000950170-24-044938.txt   183573

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acor-20240412.xsd EX-101.SCH 24851
17 EXTRACTED XBRL INSTANCE DOCUMENT acor-20240412_htm.xml XML 4710
Mailing Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965
Business Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965 914-347-4300
Acorda Therapeutics, Inc. (Filer) CIK: 0001008848 (see all company filings)

IRS No.: 133831168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31938 | Film No.: 24849474
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)